Management of hyperparathyroidism (PHP) in MEN2 syndromes in Europe

Hyperparathyroidism occurs in 20-30% of MEN2A syndrome patients. It is usually associated with mild disease and is frequently asymptomatic, especially in younger age. There is genotype/phenotype association and PHP is usually associated with codon 634 mutations; however association with more “rare”...

Descripción completa

Detalles Bibliográficos
Autor principal: Alevizaki, Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3599702/
https://www.ncbi.nlm.nih.gov/pubmed/23514325
http://dx.doi.org/10.1186/1756-6614-6-S1-S10
_version_ 1782263030939123712
author Alevizaki, Maria
author_facet Alevizaki, Maria
author_sort Alevizaki, Maria
collection PubMed
description Hyperparathyroidism occurs in 20-30% of MEN2A syndrome patients. It is usually associated with mild disease and is frequently asymptomatic, especially in younger age. There is genotype/phenotype association and PHP is usually associated with codon 634 mutations; however association with more “rare” mutations has also been reported. The pathology of the parathyroid glands includes hyperplasia, adenoma or a combination of the two. The optimal surgical management of this entity has not been defined yet.
format Online
Article
Text
id pubmed-3599702
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-35997022013-03-25 Management of hyperparathyroidism (PHP) in MEN2 syndromes in Europe Alevizaki, Maria Thyroid Res Review Hyperparathyroidism occurs in 20-30% of MEN2A syndrome patients. It is usually associated with mild disease and is frequently asymptomatic, especially in younger age. There is genotype/phenotype association and PHP is usually associated with codon 634 mutations; however association with more “rare” mutations has also been reported. The pathology of the parathyroid glands includes hyperplasia, adenoma or a combination of the two. The optimal surgical management of this entity has not been defined yet. BioMed Central 2013-03-14 /pmc/articles/PMC3599702/ /pubmed/23514325 http://dx.doi.org/10.1186/1756-6614-6-S1-S10 Text en Copyright ©2013 Alevizaki; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Alevizaki, Maria
Management of hyperparathyroidism (PHP) in MEN2 syndromes in Europe
title Management of hyperparathyroidism (PHP) in MEN2 syndromes in Europe
title_full Management of hyperparathyroidism (PHP) in MEN2 syndromes in Europe
title_fullStr Management of hyperparathyroidism (PHP) in MEN2 syndromes in Europe
title_full_unstemmed Management of hyperparathyroidism (PHP) in MEN2 syndromes in Europe
title_short Management of hyperparathyroidism (PHP) in MEN2 syndromes in Europe
title_sort management of hyperparathyroidism (php) in men2 syndromes in europe
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3599702/
https://www.ncbi.nlm.nih.gov/pubmed/23514325
http://dx.doi.org/10.1186/1756-6614-6-S1-S10
work_keys_str_mv AT alevizakimaria managementofhyperparathyroidismphpinmen2syndromesineurope

Ejemplares similares